COLUMBIA, Md.--(BUSINESS WIRE)--Celsion Corporation (NASDAQ: CLSN: Michael H. Tardugno, President and Chief Executive Officer) and Yakult Honsha Co., Ltd. (Yakult: Mr. Sumiya Hori, President) today announce that Yakult will commence pre-clinical and clinical studies of ThermoDox® to support requirements for drug registration in Japan. Celsion and Yakult have executed a letter of intent relating to the commercialization of ThermoDox® for the Japanese markets, which is subject to the execution of definitive agreements.
